Lindbrook Capital, LLC Biotechnology

Lindbrook Capital, LLC

$1.09 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VIR Vir Biotechnology, Inc.	$919M	$2,000 0.0% of portfolio	396	Q4 2024 Added 102.04%
FDMT 4 D Molecular Therapeutics, Inc.	$121M	$1,000 0.0% of portfolio	337	Q4 2024 Added 243.88%
ERAS Erasca, Inc.	$181M	$1,000 0.0% of portfolio	745	Q4 2024 Reduced 18.31%
IGMS Igm Biosciences, Inc.	$34.8M	$1,000 0.0% of portfolio	194	Q4 2024 Added 4.86%
ITOS I Teos Therapeutics, Inc.	$245M	$1,000 0.0% of portfolio	172	Q4 2024 Reduced 6.52%
KROS Keros Therapeutics, Inc.	$295M	$1,000 0.0% of portfolio	89	Q4 2024 Reduced 21.24%
MNKD Mannkind Corp	$1.35B	$1,000 0.0% of portfolio	300	Q3 2024 Added 206.12%
ORIC Oric Pharmaceuticals, Inc.	$292M	$1,000 0.0% of portfolio	214	Q4 2024 Reduced 18.32%
PHAT Phathom Pharmaceuticals, Inc.	$245M	$1,000 0.0% of portfolio	155	Q4 2024 New
SANA Sana Biotechnology, Inc.	$430M	$1,000 0.0% of portfolio	901	Q4 2024 Added 890.11%
TSHA Taysha Gene Therapies, Inc.	$79.3M	$1,000 0.0% of portfolio	770	Q4 2024 Added 243.75%
XNCR Xencor Inc	$804M	$1,000 0.0% of portfolio	67	Q4 2024 Reduced 71.49%
ETNB 89bio, Inc.	$412M	$0 0.0% of portfolio	5	Q4 2024 Reduced 95.37%
ALLO Allogene Therapeutics, Inc.	$234M	$0 0.0% of portfolio	9	Q4 2024 New
ALT Altimmune, Inc.	$283M	$0 0.0% of portfolio	61	Q4 2024 Reduced 27.38%
AMRN Amarin Corp Plcuk	$177M	$0 0.0% of portfolio	200	Q4 2021 New
ABUS Arbutus Biopharma Corp	$496M	$0 0.0% of portfolio	284	Q4 2023 New
ACLX Arcellx, Inc.	$3.13B	$0 0.0% of portfolio	7	Q4 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	805	Q4 2024 Reduced 5.85%
AXLA Axcella Health Inc.	$0	$0 0.0% of portfolio	80	Q3 2023 Reduced 96.0%
SAVA Cassava Sciences Inc	$111M	$0 0.0% of portfolio	96	Q4 2024 Reduced 1.03%
CRMD Cor Medix Inc.	$452M	$0 0.0% of portfolio	81	Q3 2024 New
NTLA Intellia Therapeutics, Inc.	$684M	$0 0.0% of portfolio	63	Q4 2024 Reduced 27.59%
JANX Janux Therapeutics, Inc.	$1.27B	$0 0.0% of portfolio	12	Q3 2024 Added 20.0%
KURA Kura Oncology, Inc.	$525M	$0 0.0% of portfolio	79	Q4 2024 Reduced 11.24%
LCTX Lineage Cell Therapeutics, Inc.	$84.9M	$0 0.0% of portfolio	29	Q1 2024 Reduced 98.35%
NUVL Nuvalent, Inc.	$3.34B	$0 0.0% of portfolio	3	Q4 2024 Reduced 62.5%
OCUL Ocular Therapeutix, Inc	$573M	$0 0.0% of portfolio	68	Q2 2024 New
PLRX Pliant Therapeutics, Inc.	$76.9M	$0 0.0% of portfolio	25	Q4 2024 Added 78.57%
PSTX Poseida Therapeutics, Inc.	$815M	$0 0.0% of portfolio	52	Q4 2024 New
TBPH Theravance Biopharma, Inc.	$625M	$0 0.0% of portfolio	14	Q4 2024 New
VERA Vera Therapeutics, Inc.	$749M	$0 0.0% of portfolio	12	Q4 2024 New
VCEL Vericel Corp	$2.23B	$0 0.0% of portfolio	12	Q4 2024 Reduced 55.56%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.